133 related articles for article (PubMed ID: 17944692)
1. Relative antiviral efficacy should not be inferred from cross-trial comparisons.
Hall D
HIV Med; 2007 Nov; 8(8):570-1; author reply 571-2. PubMed ID: 17944692
[No Abstract] [Full Text] [Related]
2. Relative antiviral efficacy of ritonavir-boosted darunavir and ritonavir-boosted tipranavir vs. control protease inhibitor in the POWER and RESIST trials.
Hill A; Moyle G
HIV Med; 2007 May; 8(4):259-64. PubMed ID: 17461854
[TBL] [Abstract][Full Text] [Related]
3. Hill A, Moyle G. Relative antiviral efficacy of ritonavir-boosted darunavir and ritonavir-boosted tipranavir vs. control protease inhibitor in the POWER and RESIST trials. HIV Med 2007; 8: 259-264. Methodological accuracy in cross-trial comparisons of antiretroviral regimens in multitreated patients.
Llibre JM; Pérez-Alvarez N
HIV Med; 2007 Nov; 8(8):568-70; author reply 571-2. PubMed ID: 17944691
[No Abstract] [Full Text] [Related]
4. New protease inhibitors and non-nucleoside reverse transcriptase inhibitors.
Lascar M; Cartledge JD
J HIV Ther; 2008 Jun; 13(2):40-4. PubMed ID: 18953273
[No Abstract] [Full Text] [Related]
5. New therapy for advanced HIV.
FDA Consum; 2005; 39(5):5. PubMed ID: 16419282
[No Abstract] [Full Text] [Related]
6. Protease inhibitors: the current status.
Dauer B
J HIV Ther; 2005 Dec; 10(4):72-4. PubMed ID: 16519246
[No Abstract] [Full Text] [Related]
7. Successful use of a tipranavir/ritonavir-based antiretroviral regimen following development of viral resistance to darunavir.
Pierone G; Urban T; Martin A; Mieras J; Kantor C
HIV Clin Trials; 2008; 9(2):140-1. PubMed ID: 18474499
[No Abstract] [Full Text] [Related]
8. A lame duck, a dark horse, and a goat.
Huff B
GMHC Treat Issues; 2005; 19(5-6):4-5. PubMed ID: 16193576
[No Abstract] [Full Text] [Related]
9. New protease inhibitor offers clinicians hope for better salvage therapy.
Murphy MJ
HIV Clin; 2006; 18(1):1-3. PubMed ID: 16838417
[No Abstract] [Full Text] [Related]
10. Anti-HIV agents. Tipranavir in treatment-experienced PHAs.
TreatmentUpdate; 2005; 17(1):4-5. PubMed ID: 17225315
[No Abstract] [Full Text] [Related]
11. [Desensitization to tipranavir caused by toxicodermia].
Martínez Castro B; Ferrando Piqueres R; Martínez García M; Soler Company E
Farm Hosp; 2009; 33(6):340-2. PubMed ID: 20038397
[No Abstract] [Full Text] [Related]
12. Drug resistance mutations in HIV-infected patients in the Spanish drug resistance database failing tipranavir and darunavir therapy.
Poveda E; Anta L; Blanco JL; Casado JL; Gutiérrez F; García F; Gómez-Sirvent JL; Iribarren JA; Soriano V; de Mendoza C;
Antimicrob Agents Chemother; 2010 Jul; 54(7):3018-20. PubMed ID: 20479204
[TBL] [Abstract][Full Text] [Related]
13. Darunavir offers potent new combo when used with enfuvirtide in ritonavir-boosted regimen.
Edmunds-Ogbuokiri T
HIV Clin; 2007; 19(1):1-3. PubMed ID: 17405221
[No Abstract] [Full Text] [Related]
14. Trial of tipranavir versus darunavir in treatment-experienced patients enrolling.
AIDS Patient Care STDS; 2007 Aug; 21(8):6-3. PubMed ID: 17902242
[No Abstract] [Full Text] [Related]
15. Darunavir: promising initial results.
MacArthur RD
Lancet; 2007 Apr; 369(9568):1143-4. PubMed ID: 17416241
[No Abstract] [Full Text] [Related]
16. Tipranavir demonstrates potent and durable treatment response in HIV-positive women.
AIDS Patient Care STDS; 2007 Aug; 21(8):602-3. PubMed ID: 17907309
[No Abstract] [Full Text] [Related]
17. Aptivus capsules granted full FDA approval.
AIDS Patient Care STDS; 2007 Nov; 21(11):889-90. PubMed ID: 18338430
[No Abstract] [Full Text] [Related]
18. Efficacy of a reduced dose of darunavir/ritonavir in a small cohort of antiretroviral-naïve HIV-infected patients.
Lanzafame M; Lattuada E; Rigo F; Vento S
AIDS Patient Care STDS; 2013 Jun; 27(6):315-6. PubMed ID: 23701201
[No Abstract] [Full Text] [Related]
19. Treatment response to ritonavir-boosted tipranavir versus ritonavir-boosted lopinavir in HIV-1 patients with higher lopinavir mutation scores.
Walmsley SL; Cotte L; Rusconi S; Ward DJ; Hicks CB; Meier U; Valdez H; Boucher CA
AIDS; 2007 Oct; 21(16):2245-8. PubMed ID: 18090054
[TBL] [Abstract][Full Text] [Related]
20. Durable efficacy of tipranavir-ritonavir in combination with an optimised background regimen of antiretroviral drugs for treatment-experienced HIV-1-infected patients at 48 weeks in the Randomized Evaluation of Strategic Intervention in multi-drug reSistant patients with Tipranavir (RESIST) studies: an analysis of combined data from two randomised open-label trials.
Hicks CB; Cahn P; Cooper DA; Walmsley SL; Katlama C; Clotet B; Lazzarin A; Johnson MA; Neubacher D; Mayers D; Valdez H;
Lancet; 2006 Aug; 368(9534):466-75. PubMed ID: 16890833
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
